MedTrace Logo

An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

NCT00823199 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-08-21

Study results available
· View outcomes & findings →

Summary

This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.

Conditions

Interventions

DRUG

Allopurinal

300mg once daily by mouth for four weeks

Sponsors & Collaborators

  • Bronx Psychiatric Center

    lead OTHER_GOV

Principal Investigators

  • Nigel Bark, MD · Bronx Psychiatric Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2008-08-31
Completion
2008-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00823199 on ClinicalTrials.gov